(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
05 October 2023 (05.10.2023)

WIPO | PCT

(10) International Publication Number
WO 2023/192669 A1

(51) International Patent Classification:
A61K 31/445 (2006.01) *A61K 31/395* (2006.01)
A61K 31/435 (2006.01) *A61K 31/33* (2006.01)

(21) International Application Number:
PCT/US2023/017309

(22) International Filing Date:
03 April 2023 (03.04.2023)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/326,682 01 April 2022 (01.04.2022) US

(71) Applicants: **PRAXIS PRECISION MEDICINES, INC.** [US/US]; 99 High Street, 30th Floor, Boston, Massachusetts 02110 (US). **MILANOS, Lampros** [GB/GB]; c/o Charles River, Chesterford Research Park, Saffron Walden CB10 1XL (GB).

(72) Inventors; and
(71) Applicants: **TOOP, Hamish** [AU/US]; c/o Praxis Precision Medicines, Inc., 99 High Street, 30th Floor, Boston, Massachusetts 02110 (US). **GRIFFIN, Andrew Mark** [CA/CA]; 232 Rue Barette, L'Île-Bizard, Montreal, Québec H9C 2Y7 (CA). **SUTTON, Jon** [GB/GB]; c/o Charles River, 8-9 The Spire Green Centre, Harlow, Essex CM19 5TR (GB).

(72) Inventor: **LIRA, Ricardo**; 12 Joshua Valley Road, East Lyme, Connecticut 06333 (US).

(74) Agent: **MARGOLIN, Yelena** et al.; McCarter & English, LLP, 265 Franklin Street, Boston, Massachusetts 02110 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

WO 2023/192669 A1

(54) Title: T-TYPE CALCIUM CHANNEL MODULATORS COMPRISING A PIPERAZINE OR 1,4-DIAZEPANE CORE AND METHODS OF USE THEREOF

(57) Abstract: Disclosed herein are compounds for treating a condition modulated by calcium channel ion activity and pharmaceutical compositions comprising the compounds, including the compounds comprising a piperazine core, a 1,4-diazepane core or a 1,5-diazepane core. Also disclosed herein are methods using the compounds to treat a disease or condition relating to aberrant function or activity of a T-type calcium channel.